Cancer Pain 101: A Digital, Asynchronous Intervention of Pain Management in Advanced Cancer (COPES Aim 3)

October 15, 2026 updated by: Hailey Bulls, University of Alabama at Birmingham

This is a Stage 1 study of a behavioral intervention, which means that a new intervention is being pilot tested to understand whether it is acceptable and feasible for people with advanced cancer to use. The purpose of this study is to evaluate whether a series of 3 10-minute videos may help improve prescription opioid pain management and opioid stigma for people living with advanced cancer. Approximately 45 participants will take part in this study at the University of Alabama at Birmingham. People who choose to participate in this study will complete a series of baseline questionnaires, and then will be randomized to one of two groups: 1) the group that gets the video intervention, or 2) the group that gets a written handout with information about cancer pain. About 4 weeks later, all participants will also be asked to fill out another series of questionnaires.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

45

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama at Birmingham
        • Contact:
        • Contact:
        • Principal Investigator:
          • Hailey W Bulls, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age ≥ 18 years old
  • speaks English
  • current, advanced solid tumor cancer diagnosis (stage III or IV)
  • endorses cancer-related pain (e.g,. pain, that began, worsened, and/or changed during cancer)
  • current opioid prescription OR planning to initiate opioids for cancer pain management

Exclusion Criteria:

  1. observable psychiatric disorders that would interfere with study participation (e.g., dementia, psychosis)
  2. inability to speak and read English
  3. inability to provide informed consent
  4. prior participation in aspects of this study (i.e., K08 Aims 1 and 2)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cancer Pain 101 Intervention

Participants randomized to the intervention group will have access to three 10-minute videos through a digital application. The videos cover cancer pain, pain medications, and pain self-management skills, and will be available for four weeks.

The study intervention is Cancer Pain 101. Cancer Pain 101 is a 3-part educational video series, designed to be delivered asynchronously. Each video is approximately 10 minutes long and is narrated by a multidisciplinary team, including a psychologist, oncologist, palliative care clinician, and pharmacist.

No Intervention: Educational Control

Participants in the educational control condition will receive a written handout about cancer pain, which is widely available and published by the American Cancer Society; they will not have access to the intervention videos.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants who watch at least one video
Time Frame: 4 weeks

Count participants who watch at least one video

4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hailey W Bulls, PhD, University of Alabama at Birmingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

May 1, 2027

Study Registration Dates

First Submitted

September 23, 2026

First Submitted That Met QC Criteria

September 23, 2026

First Posted (Actual)

October 1, 2026

Study Record Updates

Last Update Posted (Actual)

October 20, 2026

Last Update Submitted That Met QC Criteria

October 15, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The proposed research will include data from a total of 120 patients (75 Aims 1 and 2; 45 Aim 3) with advanced cancer. The final dataset will include self-reported demographic data and survey data from pilot trial assessments. All data in our analysis will be deidentified. No identifying information will be retained past the conclusion of the K08 study period. The data collected will be used for publication purposes and will be made available for public use upon completion of our study and the initial dissemination of our research results. Any data shared will be de-identified.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe